Sangyeul Han

Sangyeul Han has a diverse work experience spanning from 2002 to the present. Sangyeul currently serves as the CEO of INGENIA Therapeutics since July 2019. Prior to this, they held roles at Cell Signaling Technology (CST), starting as a Senior Scientist from November 2016 to July 2018, and later as a Group Leader in Molecular Biology & Antibody Engineering from August 2018 to June 2019. Before joining CST, Sangyeul worked at Samsung Advanced Institute for Technology as a Senior Scientist from September 2010 to September 2015. Sangyeul'swork focused on developing therapeutic antibody candidates for cancer, sepsis, and ocular diseases, resulting in multiple patents and a research paper. Earlier in their career, they worked as an Instructor at Harvard Medical School from June 2008 to August 2010, where they investigated the pathogenic mechanism of sporadic chordoma and identified potential treatments for chordoma patients. Prior to that, they were a Research Fellow at Massachusetts General Hospital, Harvard Medical School from May 2002 to July 2008, where they studied the molecular mechanisms of tumor suppression and neurological complications. Overall, Sangyeul Han brings a wealth of experience and expertise in molecular biology, antibody engineering, and therapeutic development to their current role as CEO.

Sangyeul Han completed their Bachelor of Science (BSc) degree in Molecular Biology from Seoul National University from 1989 to 1993. Sangyeul then pursued their Master's degree in Cell Biology from the same university, which they completed from 1993 to 1995. Following that, they furthered their education at Seoul National University and obtained a Ph.D. in Cell Biology from 1995 to 2001.